| 40.1657 0.444 (1.12%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 47.39 |
1-year : | 55.35 |
| Resists | First : | 40.57 |
Second : | 47.39 |
| Pivot price | 38.76 |
|||
| Supports | First : | 37.86 |
Second : | 36.18 |
| MAs | MA(5) : | 39.07 |
MA(20) : | 38.4 |
| MA(100) : | 36.57 |
MA(250) : | 32.97 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 78.7 |
D(3) : | 73.7 |
| RSI | RSI(14): 61 |
|||
| 52-week | High : | 40.57 | Low : | 24.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LFSC ] has closed below upper band by 1.1%. Bollinger Bands are 2.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 40.63 - 40.79 | 40.79 - 40.95 |
| Low: | 39.42 - 39.6 | 39.6 - 39.78 |
| Close: | 39.88 - 40.16 | 40.16 - 40.43 |
The F/M Emerald Life Sciences Innovation ETF (LFSC) strategically invests in pioneering life science enterprises. Its core objective is to identify companies that are well-positioned for substantial long-term growth and the creation of significant value. As an actively managed fund, LFSC benefits from a highly specialized and experienced team dedicated to conducting in-depth research into complex life sciences firms. The fund primarily targets U.S. equity securities, selecting those that demonstrate strong growth potential. Specific criteria for inclusion involve a company's leadership in technological advancement, its capacity for market disruption, or its innovative application of artificial intelligence. The expansive field of life sciences, as defined by the fund, encompasses various sectors including biotechnology, pharmaceuticals, medical diagnostics and devices, healthcare services and technologies, and synthetic biology. Stock selection is guided by a rigorous and extensive 10-step research framework. This meticulous process incorporates: Reviews of publicly accessible and external third-party information. Comprehensive peer reviews. Development of detailed financial and valuation models. In-house research and surveys. Direct engagement and interviews with company management, industry and medical experts, and supply chain representatives. Robust internal collaboration among the investment team. While its primary focus is on domestic equities, the fund retains the flexibility to allocate up to 20% of its capital to foreign companies, provided they are listed and traded on a U.S. exchange.
Sun, 12 Apr 2026
MANE Stock Price and Chart — NYSE:MANE - TradingView
Thu, 22 Jan 2026
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer - Benzinga
Sat, 22 Nov 2025
LMRI Stock Price and Chart — NASDAQ:LMRI - TradingView
Tue, 04 Nov 2025
BLLN | BillionToOne, Inc. Class A Stock Data, Price & News - Quiver Quantitative
Mon, 06 Oct 2025
Emerald Advisers and F/m Investments Launch F/m Emerald Special Situations ETF (SPIT) - Business Wire
Wed, 16 Jul 2025
ETFs Investing in Hinge Health, Inc. Class A Stocks - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|